¿Es la obesidad un factor predictivo de falta de respuesta al tratamiento en la artritis psoriásica? Actualización de una revisión sistemática

Gratacós, Jordi; Galíndez, Eva; Otón, Teresa.
Reumatol. clín. (Barc.) ; 17(5): 268-278, May. 2021. ilus, tab, graf
Artículo en Francés | IBECS (España) | ID: ibc-211930

Documentos relacionados

  1. Placebo response in psoriatic arthritis clinical trials: a systematic review and meta-analysis.
  2. Secukinumab como tratamiento biológico en la artritis psoriásica en práctica clínica real
  3. Glucagon-Like Peptide 1 Receptor Agonists in Patients With Inflammatory Arthritis or Psoriasis: A Scoping Review.
  4. Management of particular clinical situations in psoriatic arthritis: an expert's recommendation document based on systematic literature review and extended Delphi process.
  5. A clinical review of structural damage in psoriatic arthritis for dermatologists: From pathogenesis to ongoing controversies.
  6. Unmet need in rheumatology: reports from the Advances in Targeted Therapies meeting, 2023.
  7. [Update in psoriatic arthritis treatment].
  8. Exploring 5-year changes in general and skin health-related quality of life in psoriatic arthritis patients.
  9. Defining the minimal important change (MIC) and meaningful change value (MCV) for the Psoriatic Arthritis Disease Activity Score (PASDAS) in a routine practice cohort of patients with psoriatic arthritis.
  10. A cost-consequence analysis of the preferential use of secukinumab versus adalimumab for the treatment of psoriatic arthritis